Complicated Urinary Tract Infection (cUTI), a type of urinary tract infection (UTI) involving either the bladder or kidneys, is a symptomatic urinary infection that occurs in individuals with functional or structural abnormalities of the genitourinary tract, that predispose the patient to persistent infection, recurrent infection or treatment failure. UTIs are basically categorized as uncomplicated or complicated depending on the severity of the infection. These are caused by a wide range of pathogens, including gram-negative and gram-positive bacteria as well as fungi.
DelveInsight's "Complicated Urinary Tract Infections Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Complicated Urinary Tract Infections Market, historical and forecasted epidemiology, the pipeline insight as well as the Complicated Urinary Tract Infections market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Complicated Urinary Tract Infections Market key facts
Another study conducted by M. Michelle et al revealed that cUTI is a frequent cause of hospitalization across all age groups. Compared to younger patients, older patients (≥50 years) were more likely to have a cUTI due to K. pneumonia or Pseudomonas. In addition, patients ≥ 51 years, on average, had longer LOS and higher hospitalization cost relative to patients < 50 years
The most common causative agent for both uncomplicated and complicated UTIs is uropathogenic Escherichia coli (UPEC). For complicated UTIs, the order of prevalence for causative agents, following uropathogenic Escherichia coli (UPEC) (65%) as most common, is Enterococcus spp. (11%), K. pneumonia (8%), Candida spp. (7%), S. aureus (3%), P. mirabilis (2%), P. aeruginosa (2%) and group B Streptococcus (GBS) (2%) [Ana L. Flores-Mireles et al.]
Complicated Urinary Tract Infections Market Trends and Share Analysis
The Complicated Urinary Tract Infections market size shall increase during the forecast period owing to the launch of upcoming therapies in the market.
The Complicated Urinary Tract Infections market analysis section of the report helps to build the detailed comprehension of the historic, current and forecasted Complicated Urinary Tract Infections market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Complicated Urinary Tract Infections market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Complicated Urinary Tract Infections Epidemiology Forecast
The Complicated Urinary Tract Infections epidemiology section covers insights about historical and current Complicated Urinary Tract Infections patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Complicated Urinary Tract Infections Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Complicated Urinary Tract Infections Pipeline Analysis and Key Companies
The Complicated Urinary Tract Infections Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Complicated Urinary Tract Infections market or expected to get launched in the market during the study period. The analysis covers the Complicated Urinary Tract Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.
Some of the key Complicated Urinary Tract Infections companies include:
Wockhardt
Allecra
Iterum Therapeutics US Limited
Shionogi
Spero Therapeutics
And many others.
Source : Complicated Urinary Tract Infections Market Trends and Share Analysis